effectiveness of low-concentration atropine as myopia control

Abstract

INTRODUCTION: One of the many methods to successfully control myopia is atropine. Even though multiple studies have confirmed the usefulness, there is ongoing discussion on the ideal dosage. Low-concentration atropine had the most efficacy, according to several reports on atropine for the treatment of childhood myopia (ATOM) and low-concentration atropine for myopia progression (LAMP). Therefore, the aim of this study was to assess the relationship between ocular biometric components and the efficacy of low-concentration atropine as a myopia management.EVIDENCE ACQUISITION: A literature search was performed on PubMed, ScienceDirect, and SpringerLink databases using the key words “low concentration atropine,” “myopia control,” and “ocular biometric.”EVIDENCE SYNTHESIS: The results showed that eight papers in all, most of which came from Asia, were reviewed. Based on the investigations, atropine significantly affected the development of axial length (AL) and spherical equivalent (SE). Compared to placebo, low-dose atropine caused a noticeably delayed progression of SE over a period of 9-36 months.CONCLUSIONS: Based on the results, myopia can be effectively controlled with low dosages of atropine. This was demonstrated by a reduction in AL and SE advancement, and a significant decrease in myopia.

Access to Document

Other files and links

• Link to publication in Scopus

Fingerprint